`
The global rat model market was valued at USD 1.79 billion in 2025 and is projected to grow from USD 1.92 billion in 2026 to USD 3.35 billion by 2034, registering a CAGR of 7.22% during the forecast period. This robust growth reflects the expanding role of rat models in biomedical research, pharmaceutical development, and disease investigation across the globe.
Laboratory rats — both native and genetically modified — serve as critical experimental subjects that mirror human disease progression, enabling scientists to discover treatment pathways and develop new therapeutics. The U.S. alone dominates the global landscape, capturing more than 60% of the total market share, according to the National Institutes of Health (NIH).
Key Market Drivers
Rising Demand for Preclinical Research & CRISPR Advancements
The primary growth engine for the rat model market is the increasing need for reliable animal models in drug discovery and disease investigation. Rats are biologically similar to humans in numerous physiological traits, making them optimal for preclinical testing. The National Cancer Institute (NCI) reported a 15% rise in rat model adoption for cancer research in North America in 2022. The emergence of CRISPR gene-editing technology has further accelerated growth by enabling the precise development of genetically modified rat strains tailored for specific disease studies.
More Details: https://www.fortunebusinessinsights.com/rat-model-market-112049
Key Market Restraints
Ethical Concerns & Regulatory Pressures
A significant challenge constraining market expansion is the growing ethical scrutiny and tightening regulations around animal testing, particularly in Europe and North America. Research by the European Animal Research Association (EARA) shows that while over 300 European research institutions use rats annually, there is a discernible shift toward alternative models such as organ-on-chip technology and in-vitro testing approaches.
Key Market Opportunities
Precision Medicine & Rising R&D Investments
The customization of rat models for precision medicine presents a major future opportunity. CRISPR-enabled disease-specific models are opening new avenues in personalized medicine research. China, through the National Natural Science Foundation (NSFC), invests approximately USD 1 billion annually in rat model research, signaling strong momentum across Asian markets.
Segmentation Highlights
- By Type: The Transgenic segment leads due to growing demand for CRISPR-modified rat models designed for disease-specific research.
- By Species: Sprague-Dawley Rats dominate pharmaceutical testing. Per AVMA statistics, over 80% of rat models in North America are either Sprague-Dawley or Wistar strains.
- By Application: Disease Modelling holds the largest share, driven by the surge in chronic disease research and the NCI's documented 15% increase in rat model use for cancer studies.
- By End-user: The Pharmaceutical & Biotechnology segment is the largest, representing more than 70% of all drug assessments in North America (PhRMA data).
Regional Analysis
- North America leads globally with over 60% market share, backed by significant government funding, the NSF's reported USD 2 billion in annual U.S. rat model research, and over 1,000 breeding facilities (NABR).
- Europe holds the second-largest share (~25% of global revenue per the European Commission), with regulated, high-quality preclinical standards and model pricing ranging from EUR 150–EUR 400 per unit (EMA). Cardiovascular rat model usage grew by 10% in 2022 (ESC).
- Asia Pacific is the fastest-growing region, led by China's USD 1 billion annual R&D commitment. More than half of all rat models in Asia serve Contract Research Organizations (CROs) (JPMA).
Key Players
- Charles River Laboratories (U.S.)
- Inotiv, Inc. (U.S.)
- Envigo Research Models and Services (U.S.)
- GENOWAY (France)
- Laboratory Corporation of America Holdings (U.S.)
- Janvier Labs (France)
- Taconic Biosciences, Inc. (U.S.)
- Cyagen US Inc. (U.S.)
Top comments (0)